Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TOLE3: XEN1101 versus placebo for focal-onset seizures
NL-OMON60516Phase 3Recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Focal Onset Epilepsy and Focal onset seizure comparing Azetukalner with Placebo (2 arms). Primary endpoint: 50% responder rate in monthly focal seizure frequency. Started May 2023; status: recruiting.
02
Drugs
azetukalner
03
Conditions
Focal Onset EpilepsyFocal onset seizure
Beyond the preview
Go deeper on NL-OMON60516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60516.